Transcriptional regulation of the MET receptor tyrosine kinase gene by MeCP2 and sex-specific expression in autism and Rett syndrome

[1]  P. Levitt,et al.  Comparative DNA methylation among females with neurodevelopmental disorders and seizures identifies TAC1 as a MeCP2 target gene , 2013, Journal of Neurodevelopmental Disorders.

[2]  Angela D. Wilkins,et al.  An AT-Hook Domain in MeCP2 Determines the Clinical Course of Rett Syndrome and Related Disorders , 2013, Cell.

[3]  Kathryn Roeder,et al.  Rare Complete Knockouts in Humans: Population Distribution and Significant Role in Autism Spectrum Disorders , 2013, Neuron.

[4]  S. Durand,et al.  NMDA Receptor Regulation Prevents Regression of Visual Cortical Function in the Absence of Mecp2 , 2012, Neuron.

[5]  Deanna Greenstein,et al.  Autism Risk Gene MET Variation and Cortical Thickness in Typically Developing Children and Adolescents , 2012, Autism research : official journal of the International Society for Autism Research.

[6]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[7]  Kathryn Roeder,et al.  Common genetic variants, acting additively, are a major source of risk for autism , 2012, Molecular Autism.

[8]  Paul M. Thompson,et al.  Autism-Associated Promoter Variant in MET Impacts Functional and Structural Brain Networks , 2012, Neuron.

[9]  Hye-Seung Lee,et al.  Gastrointestinal and Nutritional Problems Occur Frequently Throughout Life in Girls and Women With Rett Syndrome , 2012, Journal of pediatric gastroenterology and nutrition.

[10]  D. Geschwind,et al.  Autism genetics: searching for specificity and convergence , 2012, Genome Biology.

[11]  P. Sassone-Corsi,et al.  SIRT1-mediated deacetylation of MeCP2 contributes to BDNF expression , 2012, Epigenetics.

[12]  Michael F. Walker,et al.  De novo mutations revealed by whole-exome sequencing are strongly associated with autism , 2012, Nature.

[13]  G. Coetzee,et al.  A Noncoding RNA Antisense to Moesin at 5p14.1 in Autism , 2012, Science Translational Medicine.

[14]  Allan R. Jones,et al.  Transcriptional Architecture of the Primate Neocortex , 2012, Neuron.

[15]  G. Shepherd,et al.  Synaptic microcircuit dysfunction in genetic models of neurodevelopmental disorders: focus on Mecp2 and Met , 2011, Current Opinion in Neurobiology.

[16]  Pat Levitt,et al.  The conundrums of understanding genetic risks for autism spectrum disorders , 2011, Nature Neuroscience.

[17]  Harrison W. Gabel,et al.  Genome-Wide Activity-Dependent MeCP2 Phosphorylation Regulates Nervous System Development and Function , 2011, Neuron.

[18]  J. Knowles,et al.  Olfactory neuroepithelium-derived neural progenitor cells as a model system for investigating the molecular mechanisms of neuropsychiatric disorders , 2011, Psychiatric genetics.

[19]  P. Ashwood,et al.  Association of a MET genetic variant with autism-associated maternal autoantibodies to fetal brain proteins and cytokine expression , 2011, Translational Psychiatry.

[20]  Zohar Mukamel,et al.  Regulation of MET by FOXP2, Genes Implicated in Higher Cognitive Dysfunction and Autism Risk , 2011, The Journal of Neuroscience.

[21]  A. Percy.  Rett syndrome: exploring the autism link. , 2011, Archives of neurology.

[22]  H. Van Esch.  MECP2 Duplication Syndrome , 2011, Molecular Syndromology.

[23]  Geraldine Dawson,et al.  Risk factors for autism: translating genomic discoveries into diagnostics , 2011, Human Genetics.

[24]  Michael Wigler,et al.  Rare De Novo Variants Associated with Autism Implicate a Large Functional Network of Genes Involved in Formation and Function of Synapses , 2011, Neuron.

[25]  Boris Yamrom,et al.  Rare De Novo and Transmitted Copy-Number Variation in Autistic Spectrum Disorders , 2011, Neuron.

[26]  S. Horvath,et al.  Transcriptomic Analysis of Autistic Brain Reveals Convergent Molecular Pathology , 2011, Nature.

[27]  P. Levitt,et al.  A new synaptic player leading to autism risk: Met receptor tyrosine kinase , 2011, Journal of Neurodevelopmental Disorders.

[28]  Shenfeng Qiu,et al.  Circuit-Specific Intracortical Hyperconnectivity in Mice with Deletion of the Autism-Associated Met Receptor Tyrosine Kinase , 2011, The Journal of Neuroscience.

[29]  Pat Levitt,et al.  The autism risk genes MET and PLAUR differentially impact cortical development , 2011, Autism research : official journal of the International Society for Autism Research.

[30]  D. Amaral,et al.  Conserved Subcortical and Divergent Cortical Expression of Proteins Encoded by Orthologs of the Autism Risk Gene MET , 2010, Cerebral cortex.

[31]  Marcus C. Ferguson,et al.  Prenatal polycyclic aromatic hydrocarbon exposure leads to behavioral deficits and downregulation of receptor tyrosine kinase, MET. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[32]  L. Trusolino,et al.  MET signalling: principles and functions in development, organ regeneration and cancer , 2010, Nature Reviews Molecular Cell Biology.

[33]  P. Levitt,et al.  Evidence of cell‐nonautonomous changes in dendrite and dendritic spine morphology in the met‐signaling–deficient mouse forebrain , 2010, The Journal of comparative neurology.

[34]  Kazuo Yamada,et al.  Further evidence for the role of MET in autism susceptibility , 2010, Neuroscience Research.

[35]  J. Chelly,et al.  Cell cloning-based transcriptome analysis in Rett patients: relevance to the pathogenesis of Rett syndrome of new human MeCP2 target genes , 2010, Journal of cellular and molecular medicine.

[36]  Peter A. Jones,et al.  Hypomethylation of a LINE-1 Promoter Activates an Alternate Transcript of the MET Oncogene in Bladders with Cancer , 2010, PLoS genetics.

[37]  J. Christodoulou,et al.  Downstream targets of methyl CpG binding protein 2 and their abnormal expression in the frontal cortex of the human Rett syndrome brain , 2010, BMC Neuroscience.

[38]  Pat Levitt,et al.  Association of MET with social and communication phenotypes in individuals with autism spectrum disorder , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[39]  J. D. Macklis,et al.  MeCP2 functions largely cell-autonomously, but also non-cell-autonomously, in neuronal maturation and dendritic arborization of cortical pyramidal neurons , 2010, Experimental Neurology.

[40]  Robert S. Illingworth,et al.  Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. , 2010, Molecular cell.

[41]  R. Salgia,et al.  PAX6 Is Expressed in Pancreatic Cancer and Actively Participates in Cancer Progression through Activation of the MET Tyrosine Kinase Receptor Gene* , 2009, The Journal of Biological Chemistry.

[42]  Luigi Boccuto,et al.  Further evidence that the rs1858830 C variant in the promoter region of the MET gene is associated with autistic disorder , 2009, Autism research : official journal of the International Society for Autism Research.

[43]  Jim Selfridge,et al.  The role of MeCP2 in the brain. , 2009, Annual review of cell and developmental biology.

[44]  D. Geschwind,et al.  Genetic advances in autism: heterogeneity and convergence on shared pathways. , 2009, Current opinion in genetics & development.

[45]  Taane G Clark,et al.  MET and autism susceptibility: family and case–control studies , 2009, European Journal of Human Genetics.

[46]  Christina Thaller,et al.  Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus , 2009, Human molecular genetics.

[47]  Pat Levitt,et al.  Distinct Genetic Risk Based on Association of MET in Families With Co-occurring Autism and Gastrointestinal Conditions , 2009, Pediatrics.

[48]  J. LaSalle,et al.  Reciprocal co-regulation of EGR2 and MECP2 is disrupted in Rett syndrome and autism , 2008, Human molecular genetics.

[49]  A. Bird.  The methyl-CpG-binding protein MeCP2 and neurological disease. , 2008, Biochemical Society transactions.

[50]  Chun Li,et al.  Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder , 2008, Autism research : official journal of the International Society for Autism Research.

[51]  Stephen T. C. Wong,et al.  MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription , 2008, Science.

[52]  A. Razin,et al.  MeCP2 Deficiency in the Brain Decreases BDNF Levels by REST/CoREST-Mediated Repression and Increases TRKB Production , 2007, Epigenetics.

[53]  Pat Levitt,et al.  Disruption of cerebral cortex MET signaling in autism spectrum disorder , 2007, Annals of neurology.

[54]  Jonathan Pevsner,et al.  FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice. , 2007, Human molecular genetics.

[55]  Pat Levitt,et al.  A genetic variant that disrupts MET transcription is associated with autism , 2006, Proceedings of the National Academy of Sciences.

[56]  Eric C. Griffith,et al.  Brain-Specific Phosphorylation of MeCP2 Regulates Activity-Dependent Bdnf Transcription, Dendritic Growth, and Spine Maturation , 2006, Neuron.

[57]  Dong Sun Kim,et al.  Expression profiling of clonal lymphocyte cell cultures from Rett syndrome patients , 2006, BMC Medical Genetics.

[58]  H. Zoghbi,et al.  MeCP2 dysfunction in Rett syndrome and related disorders. , 2006, Current opinion in genetics & development.

[59]  Youhua Liu,et al.  Sp1 regulates expression of MET, and ribozyme-induced down-regulation of MET in fibrosarcoma-derived human cells reduces or eliminates their tumorigenicity. , 2004, International journal of oncology.

[60]  A. Monaco,et al.  FOXP2 expression during brain development coincides with adult sites of pathology in a severe speech and language disorder. , 2003, Brain : a journal of neurology.

[61]  Eric C. Griffith,et al.  Derepression of BDNF Transcription Involves Calcium-Dependent Phosphorylation of MeCP2 , 2003, Science.

[62]  M. Cuccaro,et al.  Identification of MeCP2 mutations in a series of females with autistic disorder. , 2003, Pediatric neurology.

[63]  R. Jaenisch,et al.  Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Eric P. Hoffman,et al.  Gene Expression Profiling in Postmortem Rett Syndrome Brain: Differential Gene Expression and Patient Classification , 2001, Neurobiology of Disease.

[65]  E. Ballestar,et al.  Effects of Rett syndrome mutations of the methyl-CpG binding domain of the transcriptional repressor MeCP2 on selectivity for association with methylated DNA. , 2000, Biochemistry.

[66]  D O Stram,et al.  A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. , 2000, American journal of epidemiology.

[67]  H. Zoghbi,et al.  Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2 , 1999, Nature Genetics.

[68]  Colin A. Johnson,et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex , 1998, Nature.

[69]  A. Bird,et al.  MeCP2 Is a Transcriptional Repressor with Abundant Binding Sites in Genomic Chromatin , 1997, Cell.

[70]  Y. Shimohigashi,et al.  Sensitivity of Opioid Receptor-like Receptor ORL1 for Chemical Modification on Nociceptin, a Naturally Occurring Nociceptive Peptide* , 1996, The Journal of Biological Chemistry.

[71]  A. Bird,et al.  Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. , 1992, Nucleic acids research.

[72]  J. McGinty.  The Many Faces of MeCP2 , 2012, Neuropsychopharmacology.

[73]  Pak Chung Sham,et al.  Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits , 2003, Bioinform..